Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
Article
Pal, Sumanta K., Somford, Diederik M., Grivas, Petros, Sridhar, Srikala S., Gupta, Shilpa, Bellmunt, Joaquim, Sonpavde, Guru, Fleming, Mark T., Lerner, Seth P., Loriot, Yohann, Hoffman-Censits, Jean, Valderrama, Begoña P., Andresen, Corina, Schnabel, Marco J., Cole, Suzanne
and Daneshmand, Siamak
(2022)
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Future Oncology 18 (21), pp. 2599-2614.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Future Oncology | ||||
| Publisher | FUTURE MEDICINE LTD | ||||
| Place of Publication | LONDON | ||||
| Volume | 18 | ||||
| Number of Issue or Book Chapter | 21 | ||||
| Page Range | pp. 2599-2614 | ||||
| Date | 2022 | ||||
| Date of publication | 29 Feb 2024 13:01 | ||||
| Institutions | Medicine > Lehrstuhl für Urologie | ||||
| Identification Number |
| ||||
| Keywords | CELL-CARCINOMA; BLADDER; FUSIONS; BGJ398; ASSOCIATION; GUIDELINES; INHIBITOR; REVEALS; adjuvant cisplatin-based chemotherapy; adjuvant therapy; cisplatin-therapy refusal; FGFR3; FGFR inhibitor; fusions or rearrangements; infigratinib; muscle-invasive urothelial carcinoma; mutations; neoadjuvant cisplatin-based chemotherapy; phase III; PROOF 302; upper tract urothelial carcinoma; urothelial bladder carcinoma; urothelial carcinoma | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Partially | ||||
| Item ID | 57677 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric